Sarita Kapila, an analyst from Morgan Stanley, maintained the Buy rating on AstraZeneca (AZN – Research Report). The associated price target is p14,500.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Sarita Kapila’s rating is based on AstraZeneca’s strong growth prospects and strategic positioning in key markets. The company is expected to achieve significant double-digit growth in both revenue and earnings per share by 2025, which has helped allay investor concerns regarding its high investment spending and potential market challenges. With continued momentum in product sales, particularly for its key drugs Imfinzi, Teszpire, and Enhertu, AstraZeneca is well-positioned for potential earnings upgrades.
Furthermore, AstraZeneca’s diverse pipeline offers considerable optionality and exposure to lucrative markets, including targeted chemotherapy for cancer, cardiovascular and renal therapies, and next-generation immuno-oncology. These areas present significant upside potential and could unlock value closer to Morgan Stanley’s bullish valuation target. The upcoming year is expected to be rich in catalysts, with pivotal clinical data readouts that could positively impact AstraZeneca’s stock performance and support its long-term revenue goals.
In another report released yesterday, Bernstein also maintained a Buy rating on the stock with a £190.00 price target.